Ubiquitin-proteasome pathway — Drug Target

All drugs that target Ubiquitin-proteasome pathway — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

Immunomodulatory drug and corticosteroid

Phase 2 pipeline (1)

• Lenalidomide-Dexamethasone-DLI · Ciusss de L'Est de l'Île de Montréal · Immunomodulatory drug and corticosteroid · Oncology
  Lenalidomide is an immunomodulatory drug that targets the ubiquitin-proteasome pathway, and Dexamethasone is a corticosteroid that modulates the immune response. DLI (Donor Lymphocyte Infusion) is a form of immunotherapy that involves infusing donor lymphocytes to treat hematologic malignancies.